Vitiligo Treatment Market Research Report: By Type (non-segmental Vitiligo, Segmental vitiligo), Treatment Type (Therapy, Surgery, Medication) and End-User (Hospitals, Aesthetic Clinics) -Forecast to 2027

Vitiligo Treatment Market Forecast

Vitiligo Treatment Market is expected to cross USD 1.84 Billion by 2025 at a CAGR of 5.6%.

Market Synopsis

Vitiligo is a pigmentation disorder in which the skin's pigment-making cells known as melanocytes are lost or destroyed. As a result of which, well-defined white patches appear on the skin. Patches may occur on one section or all over the body and later may join together.

Market Influencer

Increasing prevalence of investments by government bodies on healthcare infrastructure is positively influencing the vitiligo treatment market.

Market Drivers

• More than 150,000 Americans across all age groups were treated for vitiligo in 2013, and the cost of the treatment was more than USD 328 per patient, which is three times more than rosacea and twice more than acne treatments. It is estimated that the prevalence of vitiligo is around 1-2% worldwide. Thus, the increasing number of vitiligo cases is driving the vitiligo treatment market.


• Changing lifestyle


• Growing awareness among the population


• Development of new novel therapy and drug discovery


• The increasing number of clinical trials


• The growing importance of the aesthetic appeal


• Increasing disposable income in developing countries


• Mergers & acquisitions


• Technological advancements in the treatment methods


• Increasing government support for research and development.

Market Restraints

• Lack of trained professionals to handle the equipment is hampering the vitiligo treatment market.


• Product recalls


• Stringent regulations imposed by the government bodies on medical device manufacturers is also hindering the growth of the vitiligo treatment market.

Segmentation

By Type

• 
  

  non-segmental Vitiligo: It is also known as generalized or bilateral vitiligo. It is the largest segment as the occurrence of non-segmental vitiligo is 9 out of 10 people.

  
  


• 
  

  Segmental vitiligo: It is also known as unilateral vitiligo. It spreads rapidly in the affected areas.

  
  

By Treatment Type

• 
  

  Therapy: The therapy is further segmented into light therapy and de-pigmentation.

  
  


• 
  

  Surgery: Skin grafting, blister grafting are the types of surgery for treating vitiligo.

  
  


• 
  

  Medication: It is forecasted to be the largest segment due to the number of FDA approvals, drugs in the pipeline, and the cost of vitiligo treatment through medication is less as compared to the other treatment methods.

  
  

By End-User

• 
  

  Hospitals: The largest segment, hospitals are usually the primary points for diagnosis, treatment, and rehabilitation of individuals suffering from ailments or injuries. Growing awareness and increasing efficiency of medical services are projected to drive the growth of this segment during the forecast period.

  
  


• 
  

  Aesthetic Clinics: These clinics are widely known for improving cosmetic appearance.

  
  

By Region

• 
  

  Americas: The largest regional market. The prevalence of vitiligo is high in the Americas; the region also has a well-established healthcare industry.

  
  


• 
  

  Europe: It is estimated to be the second-largest market, due to the presence of key manufacturers and increasing research and development funding along with the undergoing rigorous clinical trial.

  
  


• 
  

  Asia-Pacific: The fastest-growing regional market, Asia-Pacific, is witnessing a surge in the number of people undergoing treatments for vitiligo, and many market players are investing in the Asia-Pacific region as it has a population of approximately 4.3 billion people.

  
  


• 
  

  Middle East & Africa: The smallest market due to limited healthcare infrastructure, the dearth of technological advancements in the pharmaceutical sector.

  
  

Key Players

• Novartis AG (Basel, Basel-Stadt)


• Allergan, Inc. (Dublin, Coolock)


• Clinuvel Pharmaceuticals Limited (Melbourne, Victoria)


• Astellas Pharma Inc. (Northbrook, IL)


• Bausch Health Companies Inc. (Laval, Quebec)


• STRATA Skin Sciences (Horsham, PA)


• Reddy’s Laboratories Ltd. (India)


• Eli Lilly Company (Indianapolis, Indiana)


• Incyte Corporation (Wilmington, Delaware)


• AstraZeneca AB (Cambridge, Cambridgeshire)


• Epizyme, Inc. (Cambridge, MA)


• Baxter International Inc. (Deerfield, Illinois)


• Pfizer Inc. (New York)

Report Scope:

Report Attribute/Metric	Details
Market Size	2025: USD 1.84 Billion 2027: Significant Value
CAGR	5.6% (2019-2025)
Base Year	2019
Forecast Period	2020-2027
Historical Data	2018
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Type, Treatment Type, End-User
Geographies Covered	North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Vendors	Novartis AG (Basel, Basel-Stadt), Allergan, Inc. (Dublin, Coolock), Clinuvel Pharmaceuticals Limited (Melbourne, Victoria), Astellas Pharma Inc. (Northbrook, IL), Bausch Health Companies Inc. (Laval, Quebec), STRATA Skin Sciences (Horsham, PA), Reddy’s Laboratories Ltd. (India), Eli Lilly Company (Indianapolis, Indiana), Incyte Corporation (Wilmington, Delaware), AstraZeneca AB (Cambridge, Cambridgeshire), Epizyme, Inc. (Cambridge, MA), Baxter International Inc. (Deerfield, Illinois), Pfizer Inc. (New York)
Key Market Opportunities	New product launches and R&D Amongst major key Players
Key Market Drivers	Changing lifestyle Growing awareness among the population Development of new novel therapy and drug discovery The increasing number of clinical trials The growing importance of the aesthetic appeal Increasing disposable income in developing countries Mergers & acquisitions Technological advancements in the treatment methods Increasing government support for research and development.

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

---